Compare Bath & Body Works Inc (BBWI) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bath & Body Works Inc vs IDEXX Laboratories, Inc. — how do they compare? Bath & Body Works Inc trades at $18.26 (market cap $3.81B), while IDEXX Laboratories, Inc. trades at $573.68 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 12.1× Bath & Body Works Inc's market cap, and Bath & Body Works Inc pays a 4.24% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| BBWI | IDXX | |
|---|---|---|
Market Cap | $3.81B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.87 | $766.68 |
52-Week Low | $14.85 | $526.44 |
Enterprise Value | $7.70B | $47.12B |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBWI trades at $18.48, down 4.35% today, reflecting bearish technical signals but attractive valuations with a P/E of 5.36 and P/S of 0.54. Recent earnings show mixed results, with Q1 2026 beating estimates, while revenue has declined over five years. The company maintains strong gross margins above 43% and positive cash flow, supported by strategic expansions into Brazil and a partnership with Ulta Beauty announced in June 2026.
The stock presents a value opportunity given low multiples and analyst consensus price target of $22.11, though risks include persistent revenue declines, high debt levels, and negative shareholder equity. Investor sentiment is cautiously optimistic amid turnaround efforts, but technical weakness suggests near-term pressure.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
